Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

AMG 102 and Avastin for Recurrent Malignant Glioma
Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/9/2015
The Preston Robert Tisch Brain Tumor Center
mi
from
Durham, NC
AMG 102 and Avastin for Recurrent Malignant Glioma
Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/9/2015
The Preston Robert Tisch Brain Tumor Center
mi
from
Durham, NC
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Childrens National Medical Center
mi
from
Washington,
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Texas Children's Hospital
mi
from
Houston, TX
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  12/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 12/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Childrens Hospital Boston, Dana-Farber Cancer Institute.
mi
from
Boston, MA
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Childrens Hospital Boston, Dana-Farber Cancer Institute.
mi
from
Boston, MA
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated:  12/11/2015
Hospital for Sick Children
mi
from
Toronto,
N99-02: Melphalan and Buthionine Sulfoximine
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)
Status: Enrolling
Updated: 12/11/2015
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Lucile Salter Packer Children's Hospital
mi
from
Palo Alto, CA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Lucile Salter Packer Children's Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Duke Univ Med Ctr
mi
from
Durham, NC
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
mi
from
Atlanta, GA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
mi
from
Atlanta, GA
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Children's Hospital Boston
mi
from
Boston, MA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated:  12/11/2015
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744
Status: Enrolling
Updated: 12/11/2015
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas
Status: Enrolling
Updated:  12/13/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas
Status: Enrolling
Updated: 12/13/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas
Status: Enrolling
Updated:  12/13/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas
Status: Enrolling
Updated: 12/13/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
Proton Radiation for Low Grade Gliomas
Status: Enrolling
Updated:  12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
Proton Radiation for Low Grade Gliomas
Status: Enrolling
Updated: 12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
Status: Enrolling
Updated:  12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
Status: Enrolling
Updated: 12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/15/2015
Vall d'Hebron University Hospital
mi
from
Barcelona,
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/15/2015
Vall d'Hebron University Hospital
mi
from
Barcelona,
Click here to add this to my saved trials
A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases
A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases
A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Radiosurgery for Glioblastoma Multiforme
Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status
Status: Enrolling
Updated:  12/18/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Radiosurgery for Glioblastoma Multiforme
Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status
Status: Enrolling
Updated: 12/18/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options
Status: Enrolling
Updated:  12/18/2015
Massachusetts General Hospital
mi
from
Boston, MA
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options
Status: Enrolling
Updated: 12/18/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
Stanford Cancer Center
mi
from
Stanford, CA
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
Yale Cancer Center
mi
from
New Haven, CT
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus
mi
from
Atlanta, GA
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
Children's Hospital Boston
mi
from
Boston, MA
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated:  12/18/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
Status: Enrolling
Updated: 12/18/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials